News
MNKD
--
0.00%
--
MannKind Corporation Participating at Upcoming Conferences
WESTLAKE VILLAGE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that it will be participating at upcoming conferences
GlobeNewswire · 09/08 13:00
Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety
WESTLAKE VILLAGE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that Kevin Kaiserman, MD, has joined the company as Vice President, Medical Affairs and Safety and will assume full responsibility for leading MannKind’s medical affairs, field medical activities
GlobeNewswire · 08/31 14:00
Key Things To Understand About MannKind's (NASDAQ:MNKD) CEO Pay Cheque
Simply Wall St. · 08/24 19:28
MannKind (MNKD) in Focus: Stock Moves 8.7% Higher
MannKind (MNKD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Zacks · 08/20 13:39
MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020
GlobeNewswire · 08/07 22:00
MannKind Corporation's (MNKD) CEO Michael Castagna on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/06 03:19
MannKind (MNKD) Reports Q2 Loss, Misses Revenue Estimates
Zacks · 08/05 23:35
MannKind Corporation Reports 2020 Second Quarter Financial Results
GlobeNewswire · 08/05 21:00
MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020
GlobeNewswire · 07/29 22:00
MannKind (MNKD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Zacks · 07/29 17:33
Alejandro Galindo Joins MannKind as Chief Commercial Officer
GlobeNewswire · 07/20 14:00
Alejandro Galindo Joins MannKind As Chief Commercial Officer
Benzinga · 07/20 13:04
MannKind (MNKD) Presents At Lytham Partners Virtual Investor Growth Conference - Slideshow
Seeking Alpha - Article · 06/26 17:37
MannKind Corporation (MNKD) CEO Michael Castagna Presents at Lytham Partners Virtual Investor Growth Conference (Transcript)
Seeking Alpha - Transcript · 06/24 20:25
MNKD, HTZ, WKHS and NBR among midday movers
Seeking Alpha - Article · 06/24 16:42
MannKind (MNKD) Looks Good: Stock Adds 5.5% in Session
Zacks · 06/22 13:30
Implied Volatility Surging for MannKind (MNKD) Stock Options
Zacks · 06/18 13:49
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17)
Benzinga · 06/18 12:34
MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference
GlobeNewswire · 06/17 22:00
MannKind Presents Positive Original Analyses of Afrezza® Clinical Data at  American Diabetes Association (ADA) 80th Scientific Sessions
GlobeNewswire · 06/15 14:00
Webull provides a variety of real-time MNKD stock news. You can receive the latest news about MannKind through multiple platforms. This information may help you make smarter investment decisions.
About MNKD
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
More